Definition

Complex peptides are peptide APIs where the synthesis, purification, or analytical characterisation presents challenges significantly beyond those of a standard linear sequence. The complexity can arise from several sources: unusual length, non-natural amino acids, disulfide bridges, cyclisation, backbone modifications, or PEGylation. Any one of these factors raises the bar; combinations of them can make a peptide genuinely difficult to manufacture at pharmaceutical quality and scale.

 

What Complexity Means in Practice

Length is perhaps the most intuitive source of complexity. With each additional amino acid in a sequence, even small inefficiencies in coupling accumulate. A peptide synthesised with 99% coupling efficiency at each step sounds excellent—but for a 30-mer, that compounds to roughly 74% theoretical full-length product before purification. Sequences with consecutive hindered residues, beta-branched amino acids, or aggregation-prone motifs can perform considerably worse than that.

Structural complexity adds another dimension. Disulfide-bridged peptides require selective oxidation after chain assembly to form the correct connectivity—when multiple disulfide pairs are present, the number of possible incorrect pairings increases rapidly, and each incorrect isomer is a structurally similar impurity that is difficult to separate. Cyclic peptides need specialised cyclisation chemistry that varies by sequence. Peptides with phosphorylated, glycosylated, or lipidated residues introduce additional protecting group strategies and compatibility considerations that affect the entire synthetic plan.

At commercial scale, every element of complexity is amplified. Reagent costs increase. Purification cycles lengthen. Analytical characterisation demands expand. A CDMO that handles complex peptides well combines expertise in synthesis strategy—knowing when to apply hybrid SPPS/LPPS approaches or fragment condensation—with the analytical depth to characterise the resulting impurity profile rigorously and the purification capability to meet purity specifications at multi-kilogram scale.

 

Related Topics

Related Topics

  • Peptide CDMO
  • Solid Phase Peptide Synthesis (SPPS)
  • Large Scale Peptides
  • Peptide NCE

FAQs

  1. At what sequence length does a peptide become complex?

    There is no fixed rule, but sequences above 20 to 25 amino acids are generally considered more challenging due to accumulated coupling inefficiencies and increasing impurity diversity. Shorter sequences with difficult residues or structural modifications can be equally demanding.

  1. How do disulfide bridges complicate synthesis?

    After chain assembly, the free cysteines need to be oxidised selectively to form the correct disulfide bonds. For peptides with multiple bridges, the risk of scrambled pairings is real and requires careful oxidation strategy and analytical verification of the correct connectivity.

  1. What analytical methods characterise complex peptides?

    LC-MS for molecular weight confirmation and sequence verification, reversed-phase HPLC for purity, peptide mapping for positional impurity identification, amino acid analysis for composition, and circular dichroism where secondary structure needs to be confirmed.

  1. Can SPPS alone handle complex peptides?

    For very long or heavily modified sequences, SPPS alone may not be sufficient. Hybrid approaches—assembling protected fragments by liquid phase synthesis and then coupling them—can improve the overall yield and purity profile for the most demanding cases.

  1. What production scale is achievable for complex peptides?

    Multi-kilogram GMP production of complex peptides is feasible with the right infrastructure—large SPPS or LPPS reactors, high-throughput preparative HPLC, and validated lyophilisation capability. The technical bar is high but the scale is achievable.

 

Talk to Neuland's peptide team about synthesis strategies for your complex peptide programme. Explore Peptide Services